Literature DB >> 25859504

A Case of SSRI Induced Irreversible Parkinsonism.

Siddharth Dixit1, Shahbaj A Khan1, Sudip Azad2.   

Abstract

Serotonin specific reuptake inhibitors (SSRI) are widely used antidepressants for variety of clinical conditions and have found popularity. They are sometimes associated with extrapyramidal side effects including Parkinsonism. We report a case of generalized anxiety disorder on treatment with SSRI (fluoxetine / sertraline) who developed irreversible Parkinsonism. SSRI are known to cause reversible or irreversible motor disturbances through pathophysiological changes in basal ganglion motor system by altering the dopamine receptors postsynaptically. Clinician should keep risk benefit ratio in mind and change of antidepressant of different class may be considered. Case is reported to alert physicians to possibility of motor system damage while treating with SSRI.

Entities:  

Keywords:  Drug induced parkinsonism; Epidemiology; Fluoxetine; Sertraline

Year:  2015        PMID: 25859504      PMCID: PMC4378786          DOI: 10.7860/JCDR/2015/11394.5583

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  14 in total

1.  Parkinsonism and Parkinson's disease associated with long-term administration of sertraline.

Authors:  M A Pina Latorre; P J Modrego; F Rodilla; C Catalán; M Calvo
Journal:  J Clin Pharm Ther       Date:  2001-04       Impact factor: 2.512

2.  Extrapyramidal symptoms after Fluoxetine.

Authors:  B K Dutta; A Saha; I V Nagesh
Journal:  Med J Armed Forces India       Date:  2013-08-02

Review 3.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

4.  Drug-induced parkinsonism.

Authors:  Federico Eduardo Micheli; María Graciela Cersósimo
Journal:  Handb Clin Neurol       Date:  2007

5.  Escitalopram-induced Parkinsonism.

Authors:  Sertaç Ak; A Elif Anıl Yağcıoğlu
Journal:  Gen Hosp Psychiatry       Date:  2013-10-05       Impact factor: 3.238

6.  [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.

Authors:  Mordechai Lorberboym; Therese A Treves; Eldad Melamed; Yair Lampl; Mark Hellmann; Ruth Djaldetti
Journal:  Mov Disord       Date:  2006-04       Impact factor: 10.338

7.  SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

Authors:  G Dell'Agnello; R Ceravolo; A Nuti; G Bellini; A Piccinni; C D'Avino; L Dell'Osso; U Bonuccelli
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

Review 8.  Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.

Authors:  Subramoniam Madhusoodanan; Lada Alexeenko; Renata Sanders; Ronald Brenner
Journal:  Ann Clin Psychiatry       Date:  2010-08       Impact factor: 1.567

9.  Citalopram-induced parkinsonian syndrome: case report.

Authors:  Vladimir Miletić; Maja Relja
Journal:  Clin Neuropharmacol       Date:  2011 Mar-Apr       Impact factor: 1.592

Review 10.  Epidemiology of Parkinson's disease and movement disorders in India: problems and possibilities.

Authors:  U B Muthane; Mona Ragothaman; G Gururaj
Journal:  J Assoc Physicians India       Date:  2007-10
View more
  4 in total

1.  Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case-Control Study in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hyun Soon Sohn; Jin-Won Kwon
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Parkinsonism secondary to duloxetine use: a case report.

Authors:  Arzu Bayrak; Bugra Cetin; Handan Meteris; Sermin Kesebir
Journal:  North Clin Istanb       Date:  2015-12-25

Review 3.  Neuron-Astrocyte Interactions in Parkinson's Disease.

Authors:  Ikuko Miyazaki; Masato Asanuma
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

4.  Respecting the Patient's Choice: A Case of Possible Drug-Induced Parkinsonism.

Authors:  Megan R Undeberg; Kimberly C McKeirnan; David Easley
Journal:  Pharmacy (Basel)       Date:  2022-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.